
USD
+$0.00
(+0.00%
)At Close (As of Nov 13, 2025)
$55.07B
Market Cap
35.19
P/E Ratio
5.46
EPS
$248.00
52 Week High
$161.47
52 Week Low
HEALTHCARE
Sector
| Field | Value (None) |
|---|---|
| Gross Profit | $9.9B |
| Total Revenue | $22B |
| Cost Of Revenue | $12B |
| Costof Goods And Services Sold | $12B |
| Operating Income | $2.6B |
| Selling General And Administrative | - |
| Research And Development | $1.3B |
| Operating Expenses | $7.3B |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | $613M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.5B |
| Income Before Tax | $1.9B |
| Income Tax Expense | $204M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | $2.5B |
| Ebitda | $5B |
| Net Income | $1.7B |
| Field | Value (None) |
|---|---|
| Total Assets | - |
| Total Current Assets | - |
| Cash And Cash Equivalents At Carrying Value | - |
| Cash And Short Term Investments | - |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | - |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | - |
| Other Non Current Assets | - |
| Total Liabilities | - |
| Total Current Liabilities | - |
| Current Accounts Payable | - |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | - |
| Total Non Current Liabilities | - |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | - |
| Other Current Liabilities | - |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | - |
| Treasury Stock | - |
| Retained Earnings | - |
| Common Stock | - |
| Common Stock Shares Outstanding | $287M |
| Field | Value (None) |
|---|---|
| Operating Cashflow | $3.4B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2.5B |
| Capital Expenditures | $760M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$818M |
| Cashflow From Financing | -$3.6B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $1.2B |
| Dividend Payout Common Stock | $1.2B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$1B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $1.7B |
| Field | Value (None) |
|---|---|
| Gross Profit | $9.9B |
| Total Revenue | $22B |
| Cost Of Revenue | $12B |
| Costof Goods And Services Sold | $12B |
| Operating Income | $2.6B |
| Selling General And Administrative | - |
| Research And Development | $1.3B |
| Operating Expenses | $7.3B |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | $613M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.5B |
| Income Before Tax | $1.9B |
| Income Tax Expense | $204M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | $2.5B |
| Ebitda | $5B |
| Net Income | $1.7B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-12-08 |
| Declaration Date | 2025-11-06 |
| Record Date | 2025-12-08 |
| Payment Date | 2025-12-31 |
| Amount | 1.05 |
Sector: HEALTHCARE
Industry: MEDICAL INSTRUMENTS & SUPPLIES
Becton, Dickinson and Company (BDX) is a leading American multinational medical technology company renowned for its development and production of critical medical devices, instrument systems, and reagents that significantly improve global healthcare outcomes. With a diversified portfolio that supports a wide array of diagnostic and therapeutic procedures, BDX effectively addresses the evolving needs of the healthcare community while providing analytical and consulting services to enhance its operational footprint. Driven by a robust commitment to innovation, underscored by considerable investments in research and development, BDX is poised to capitalize on emerging trends in the medical technology sector, solidifying its position as a key player in advancing healthcare solutions.